


# ONCOLYTIC VIRUSES SYMPOSIUM

25 May 2021 | BST (UTC+1)

Symposium Brochure



## KEY SPEAKERS INCLUDE



Romain Micol  
**Combined  
Therapeutics**



İnanç Ortaç  
**DevaCell  
Inc.**



Lorena Lerner  
**Oncorus**



Patrik Erlmann  
**ViraTherapeutics  
GmbH**



Víctor Cervera  
Carrascón  
**TILT Biotherapeutics**

**Book Online:** [www.oxfordglobal.co.uk/virtual-symposium-oncolytic-viruses/](http://www.oxfordglobal.co.uk/virtual-symposium-oncolytic-viruses/)

**Join the Conversation:** @ImmunoOncConf



OXFORD  
GLOBAL  
CONFERENCES

# KNOWLEDGE SHARING & NETWORKING

FROM THE COMFORT OF YOUR HOME



Hear from and meet with the leading figures in the oncolytic virus field, offering innovative case studies on the latest strategies from discovery through to the clinic



Interact with fellow attendees and speakers during the live Q&As, taking place across the day and through our interactive panel discussion on 'The challenges for oncolytic virus therapies in clinical trials'



Explore how companies are accelerating oncolytic viruses to the clinic. Presentations consider the best strategies, including combination virotherapies, likely to succeed in the clinic and deliver maximum patient benefit



Gain insights into how oncolytic viruses can trigger an immune response in the body against cancer, with consideration of the mechanistics of viruses, tumour biology and the tumour microenvironment



View new platforms to tackle key challenges facing oncolytic virus therapies, including immune response, tumour resistance and gene selection

## Topic Areas Include:

### Theme One: Engineering

#### Engineering & Translational Strategies To Develop Oncolytic Virus Immunotherapy

- Mechanistic understanding of viruses and tumour biology
- Engineering and optimization strategies to improve delivery, oncolysis and specificity of therapies
- Preclinical validation to ensure efficacy of therapies before clinical trials
- Targeting the tumour microenvironment
- Understanding the importance of therapeutic gene selection

### Theme Two: Clinical

#### Accelerating Oncolytic Virus Immunotherapy To The Clinic

- Challenges of safety and immune response to therapies in clinical trials
- Combination virotherapy strategies to enhance therapeutic results
- Delivering oncolytic viruses into solid tumours
- Developing biomarkers for therapies in clinical trials
- Selection of the best route of administration for immunotherapies in clinical trials

Featuring presentations by these companies and more

CARDIFF  
UNIVERSITY



Oncorus®

sorrento

targovax

ViraTherapeutics

VYRIAD

WESTERN  
ONCOLYTICS

# Oncolytic Viruses Symposium

## LIVE & INTERACTIVE CONTENT SCHEDULE

Please see the full programme for the conference below. Where possible, sessions will be made available OnDemand after the scheduled time slot.  
*Please note: Access to OnDemand sessions will only be available to delegates who purchase a full access pass*

All Times Shown are BST (UTC+1)

25 MAY 2021

08:20  
-  
08:25



### Oxford Global's Welcome Address

08:25  
-  
08:30

### Headliner Sponsor Welcome Address

08:30  
-  
08:55

### Keynote Address: Engineering Immunotherapies For Enhanced Efficacy

ENGINEERING

PATRIK ERLMANN, Head of Research & Development,  
**ViraTherapeutics GmbH**

08:55  
-  
09:20

### Oncolytic Adenovirus With Hyaluronidase Activity That Evades Neutralizing Antibodies: VCN-11

ENGINEERING

- VCN-11 is a new oncolytic adenovirus that expresses hyaluronidase and displays an albumin-binding domain on its capsid
- VCN-11 has shown a good efficacy and safety profile in different animal models
- Hyaluronidase expression allows VCN-11 to disrupt the tumor extracellular matrix favoring viral dissemination
- An Albumin Shield (ABS) protects VCN-11 from antibody neutralization and enables effective readministration

MIRIAM BAZAN-PEREGRINO, Research & Development Director,  
**VCN Biosciences SL**

09:20  
-  
09:45

### Headliner Sponsor Presentation

*For sponsorship opportunities, please contact  
[sponsorship@oxfordglobal.co.uk](mailto:sponsorship@oxfordglobal.co.uk)*

09:45  
-  
10:10

### ONCOS-102 In Combination With Chemotherapy And Check Point Inhibition In Solid Tumours

ENGINEERING

- Phase I data and rationale for further development
- Combination with chemotherapy in mesothelioma
- Combination with pembrolizumab in melanoma

MAGNUS JADERBERG, Chief Medical Officer,  
**Targovax**

10:10  
-  
10:25

### Session Wrap-Up: Live Q&A With Our Speakers

PATRIK ERLMANN, Head of Research & Development, ViraTherapeutics GmbH  
MIRIAM BAZAN-PEREGRINO, Research & Development Director, VCN Biosciences SL  
MAGNUS JADERBERG, Chief Medical Officer, Targovax

10:25  
-  
10:45

### Morning Break & Networking Activities

*Please take a moment to join our drop in networking room on our virtual platform to meet  
and greet with other conference attendees for a friendly chat.*

10:45  
-  
11:10

### A Novel Cell Entry Mechanism To Facilitate Highly Efficient Infection Of Cancer Cell Lines

ENGINEERING

ALAN PARKER, Professor of Translational Virotherapies,  
**Cardiff University**

11:10  
-  
11:35

### Engineering Oncolytic Viruses To Enable Antitumour T-Cell Responses

ENGINEERING

VÍCTOR CERVERA CARRASCÓN, Head of Immunology,  
**TILT Biotherapeutics**

11:35  
-  
12:05

### Sponsor Presentation

Senior Representative,  
**WuXi AppTec**



# Oncolytic Viruses Symposium

## LIVE & INTERACTIVE CONTENT SCHEDULE

Please see the full programme for the conference below. Where possible, sessions will be made available OnDemand after the scheduled time slot.  
*Please note: Access to OnDemand sessions will only be available to delegates who purchase a full access pass*

25 MAY 2021

### Innovative mRNA Platform Which Directs And Enhances Virotherapies

ENGINEERING

ROMAIN MICOL, President, Chief Executive Officer and Co-Founder,  
**Combined Therapeutics**

### Session Wrap-Up: Live Q&A With Our Speakers

ALAN PARKER, Professor of Translational Virotherapies, **Cardiff University**  
VÍCTOR CERVERA CARRASCÓN, Head of Immunology, **TILT Biotherapeutics**  
Senior Representative, **WuXi AppTec**  
ROMAIN MICOL, President, Chief Executive Officer and Co-Founder, **Combined Therapeutics**

### Lunch Break & Networking Activities

*Please take a moment to join our drop in networking room on our virtual platform to meet and greet with other conference attendees for a friendly chat.*

### Making Immune Cold Pancreatic Cancer Hot By Oncolytic Virotherapy - Preliminary Clinical Results

CLINICAL

- Pancreatic cancer is commonly unresponsive to immunotherapy due to the "immune cold" tumor microenvironment
- LOAd703 is an oncolytic virus encoding TMZ-CD40L and 41BBL that stimulate immune reactions that attracts T cells
- In this presentation we show preliminary clinical data that LOAd703 can make immune cold tumors hot and share data from our ongoing trials

ANGELICA LOSKOG, Chief Executive Officer & Chief Scientific Officer,  
**Lokon Pharma AB**

### A Dual Pipeline Strategy Bringing Potent Vaccinia-Based Oncolytic Immunotherapies To The Clinic

CLINICAL

STEVE THORNE, Chief Scientific Officer,  
**Western Oncolytics**

### Sponsor Presentation

Senior Representative,  
**ABL, Inc.**



### Panel Discussion: The Importance Of Gene Selection For Oncolytic Virus Therapies

ENGINEERING

- The importance of uptake, transgene expression, and intrinsic tumour sensitivities
- Constructs for diverse delivery approaches
- Unique challenges for cancer gene therapy

**Moderator:** TBA

#### Panellists:

INANÇ ORTAÇ, Chief Scientific Officer, **DevaCell Inc.**  
ANGELICA LOSKOG, Chief Executive Officer & Chief Scientific Officer, **Lokon Pharma AB**

### Enhancing Systemic Immune Responses With Viral Immunotherapies

ENGINEERING

LORENA LERNER, Vice President of Molecular Biology and Virology,  
**Oncorus**

# Oncolytic Viruses Symposium

## LIVE & INTERACTIVE CONTENT SCHEDULE

Please see the full programme for the conference below. Where possible, sessions will be made available OnDemand after the scheduled time slot.  
*Please note: Access to OnDemand sessions will only be available to delegates who purchase a full access pass*

25 MAY 2021

### **Session Wrap-Up: Live Q&A With Our Speakers**

15:15 - 15:30  
STEVE THORNE, Chief Scientific Officer, **Western Oncolytics**  
Senior Representative, **ABL, Inc.**  
LORENA LERNER, Vice President of Molecular Biology and Virology, **Oncorus**  
ANGELICA LOSKOG, Chief Executive Officer & Chief Scientific Officer, **Lokon Pharma AB**

### **Afternoon Break & Networking Activities**

*Please take a moment to join our drop in networking room on our virtual platform to meet and greet with other conference attendees for a friendly chat.*

### **TBC**

16:15 - 16:40  
SHRUTHI NAIK, Vice President of Comparative Oncology,  
**Vyriad**

CLINICAL

### **Bispecific-Armed Oncolytic Virus**

16:40 - 17:05  
DAMIEN BRESSON, Director Immuno-Oncology,  
**Sorrento Therapeutics**

ENGINEERING

### **Confirming Signaling Efficacy Of CAL1 Vaccinia Virus**

17:05 - 17:30  
ANTONIO SANTIDRIAN, Vice President, Research & Development and Translational Oncology,  
**Calidi Biotherapeutics**

ENGINEERING

### **Engineered Adenoviral (Ad5) Viral Vector For A Synthetic Vector Platform**

17:30 - 17:45  
INANÇ ORTAÇ, Chief Scientific Officer,  
**DevaCell Inc.**

ENGINEERING

### **Session Wrap-Up: Live Q&A With Our Speakers**

17:45 - 18:00  
INANÇ ORTAÇ, Chief Scientific Officer, **DevaCell Inc.**  
DAMIEN BRESSON, Director Immuno-Oncology, **Sorrento Therapeutics**  
ANTONIO SANTIDRIAN, Vice President, Research & Development and Translational Oncology, **Calidi Biotherapeutics**  
SHRUTHI NAIK, Vice President of Comparative Oncology, **Vyriad**

**End of Symposium**





## FORTHCOMING EVENTS

### Biologics Series

[www.oxfordglobal.co.uk/biologics](http://www.oxfordglobal.co.uk/biologics)

- Biologics Europe: Online**  
26 - 27 April 2021 | BST (UTC+1)
- Oligonucleotides: Chemistry & Therapeutics Symposium**  
28 April 2021 | BST (UTC+1)
- Biologics UK: In-Person**  
06 - 07 September 2021 | London, UK
- Biotherapeutics US: Online**  
17 - 18 November 2021 | EST (UTC-5)

### Biomarkers Series

[www.oxfordglobal.co.uk/biomarkers](http://www.oxfordglobal.co.uk/biomarkers)

- Flow Cytometry & Multiplex Tools Symposium**  
08 April 2021 | BST (UTC+1)
- Biomarkers Week: Online**  
17 - 21 May 2021 | BST (UTC+1)
- Advancing Biomarker Analysis Europe: Online**  
14 - 16 September 2021 | BST (UTC+1)
- Biomarkers UK: In-Person**  
08 - 09 November 2021 | Manchester, UK
- Digital Biomarkers US: Online**  
07 - 08 December 2021 | EDT (UTC-4)
- Biomarkers US: In-Person**  
07 - 08 February 2022 | San Diego, USA

### Cell Series

[www.oxfordglobal.co.uk/cell](http://www.oxfordglobal.co.uk/cell)

- Gene Therapy Europe: Online**  
05 - 06 May 2021 | BST (UTC+1)
- Cell UK: In-Person**  
28 - 29 October 2021 | London, UK
- 3D Cell Culture Symposium**  
02 December 2021 | GMT (UTC+0)

### Discovery Series

[www.oxfordglobal.co.uk/discovery](http://www.oxfordglobal.co.uk/discovery)

- Virtual Symposium: Targeted Protein Degradation & PROTAC**  
16 - 17 February 2021 | GMT (UTC+0)
- Organoid Discovery Symposium**  
13 April 2021 | BST (UTC+1)
- Discovery Week: Online**  
01 - 04 June 2021 | BST (UTC+1)
- Discovery UK: In-Person**  
26 - 27 October 2021 | London, UK
- Discovery Chemistry US: Online**  
15 - 16 November 2021 | EST (UTC-5)

### Formulation & Delivery Series

[oxfordglobal.co.uk/formulation](http://oxfordglobal.co.uk/formulation)

- Drug Delivery Devices Symposium**  
10 March 2021 | GMT (UTC+0)
- Formulation & Delivery Europe: Online**  
20 - 21 April 2021 | BST (UTC+1)
- RNA Therapeutics & Delivery US: Online**  
29 - 30 June 2021 | EDT (UTC-4)
- Formulation & Delivery UK: In-Person**  
21 - 22 September 2021 | London, UK
- Pharma Manufacturing Europe: Online**  
10 - 11 November 2021 | GMT (UTC+0)
- Formulation & Delivery US: In-Person**  
01 - 02 February 2022 | San Diego, USA

### Immuno Series

[www.oxfordglobal.co.uk/immuno](http://www.oxfordglobal.co.uk/immuno)

- Oncolytic Viruses Symposium**  
25 May 2021 | BST (UTC+1)
- Immuno Week: Online**  
06 - 09 July 2021 | BST (UTC+1)
- Immuno UK: In-Person**  
13 - 14 October 2021 | London, UK
- Immuno US: In-Person**  
07 - 08 February 2022 | San Diego, USA

### NextGen Omics Series

[www.oxfordglobal.co.uk/omics](http://www.oxfordglobal.co.uk/omics)

- Spatial Biology Europe: Online**  
14 - 16 April 2021 | BST (UTC+1)
- Spatial Biology US: Online**  
27 - 30 September 2021 | EST (UTC-5)
- NextGen Omics UK: In-Person**  
04 - 05 November 2021 | London, UK
- NextGen Omics US: In-Person**  
25 - 26 January 2022 | Boston, USA

### PharmaTec Series

[www.oxfordglobal.co.uk/pharmatec](http://www.oxfordglobal.co.uk/pharmatec)

- PharmaTec UK: In-Person**  
08 - 09 September 2021 | London, UK
- Networking Dinner Events**  
October / November / December 2021

In-Person Event   Online Event   Online Symposium

## COMPLIMENTARY RESOURCES

Visit [www.oxfordglobal.co.uk/hub/](http://www.oxfordglobal.co.uk/hub/) to gain access to our complimentary resources, including Webinar Recordings, Videos, Speaker Q&As, Newsletters, Reports, and much more!



Oxford Global Marketing Ltd.

2nd Floor, Godstow Court  
Minns Business Park  
Botley, Oxford, OX2 0JB

Tel: +44 (0)1865 248455  
Fax: +44 (0)1865 250985  
[www.oxfordglobal.co.uk](http://www.oxfordglobal.co.uk)



Join the Conversation

@ImmunoOncConf  
#IMMUNOSeries21